From: Systematic integration of molecular and clinical approaches in HCV-induced hepatocellular carcinoma
S-HCV | LIHC | L-HCV | LIHC |
---|---|---|---|
(n = 9) | P-Value | (n = 17) | P-Value |
hsa-miR-27a-3p | 0.012 | hsa-miR-194-5p | 0.12 |
hsa-miR-21-5p | 2.60E-34 | hsa-miR-215-5p | 3.40E-05 |
hsa-miR-23a-3p | 0.17 | hsa-miR-10b-5p | 1.40E-22 |
hsa-miR-8069 | 0.71 | hsa-miR-181a-5p | 0.044 |
hsa-miR-4286 | 1.80E-06 | hsa-miR-455-3p | 1.40E-16 |
hsa-miR-939-5p | 0.001 | hsa-miR-92a-3p | 0.1 |
hsa-miR-151a-5p | 3.00E-06 | hsa-miR-6740-5p | 0.72 |
hsa-miR-29b-3p | 0.0085 | hsa-miR-6875-5p | 0.15 |
hsa-miR-1260b | 0.27 | hsa-miR-320e | 0.014 |
 |  | hsa-miR-6717-5p | 0.00087 |
 |  | hsa-miR-6127 | 0.71 |
 |  | hsa-miR-6879-5p | 0.71 |
 |  | hsa-miR-6131 | 0.71 |
 |  | hsa-miR-483-5p | 5.30E-07 |
 |  | hsa-let-7a-5p | 0.00033 |
 |  | hsa-miR-7641 | 0.69 |
 |  | hsa-let-7f-5p | 0.094 |